Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

August 31, 2009

Conditions

Parkinson's DiseaseL-dopa Induced Dyskinesia

Interventions

DRUG

AFQ056

DRUG

Placebo

Trial Locations (5)

Novartis Investigative Site, Dresden

Novartis Investigative Site, Kassel

Novartis Investigative Site, Leun-Biskirchen

Novartis Investigative Site, Marburg

Novartis Investigative Site, Tübingen